LXEO — Lexeo Therapeutics, Inc. - Common Stock
Session close: $3.23. Regular-session share volume: 27,048,458. Change from previous close: +12.54%.
Key developments
The company said the FDA is open to guideline-defined non-sustained ventricular tachycardia as a primary surrogate endpoint supporting potential accelerated approval, and Lexeo is designing a pivotal study around it. Final design and confirmatory strategy remain subject to future FDA discussions, leaving regulatory risk.
Company news Lexeo Therapeutics Announces Positive Interim Data from HEROIC-PKP2 Phase I/II Clinical Trial · Company news Lexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Reports Third Quarter 2026 Financial Results
News sources
Company news Lexeo Therapeutics Announces Positive Interim Data from HEROIC-PKP2 Phase I/II Clinical Trial · Company news Lexeo Therapeutics shares surge 25% on interim data for LX2020 gene therapy · Company news Lexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Reports Third Quarter 2026 Financial Results · Company news Lexeo Therapeutics Cuts Arrhythmia Burden by 80% in Genetic Heart Disease Study · Company news Cantor Fitzgerald Maintains Overweight on Lexeo Therapeutics, Raises Price Target to $37 · Company news Lexeo Therapeutics Announces Interim Data From Its Ongoing HEROIC-PKP2 Phase I/II Clinical Trial Of LX2020 For Treatment Of PKP2 Arrhythmogenic Cardiomyopathy; Across Ten Participants, Including Nine With At Least 12 Months Of Follow-up, Treatment With LX2020 Was Generally Well Tolerated · Company news Lexeo Therapeutics Q3 EPS $(0.43) Misses $(0.33) Estimate